Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature

Melanoma and Skin CancerImmunotherapy

Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review

J Clin Neuromuscul Dis.

Supakornnumporn S, Katirji B

doi: 10.1097/ CND.0000000000000193.

Melanoma and Skin Cancer

[Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma]

Ann Dermatol Venereol.

Malmontet T, Dousset L, Gerard E, Ouhabrache N, Pham-Ledard A, Beylot-Barry M

doi: 10.1016/j.annder.2019.08.019.

Melanoma and Skin CancerImmunotherapy

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review

Neuromuscul Disord.

Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA

doi: 10.1016/j.nmd.2017.01.002.

Melanoma and Skin Cancer

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors

Br J Dermatol.

Gault A, Anderson AE, Plummer R, Stewart C, Pratt AG, Rajan N

doi: 10.1111/bjd.19750.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin Cancer

[Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab]

Ann Dermatol Venereol.

Delaitre L, Martins-Héricher J, Truchot E, Denis D, Prophette B, Maillard H, Bénéton-Benhard N

doi: 10.1016/j.annder.2019.10.031.

Immunotherapy

Autoimmune-related bleeding occurring during combined immunotherapy for lung cancer - Case report

Rev Mal Respir.

Eberst G, Lakhzoum W, Tomasini P, Andreotti N, Abcaya J, Mascaux C, Barlesi F

doi: 10.1016/j.rmr.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Acquired generalized lipodystrophy under immune checkpoint inhibition

Br J Dermatol.

Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski AM, Arangalage D, Battistella M, Gautier JF, Lebbe C, Delyon J, PATIO group

doi: 10.1111/bjd.18124.

Melanoma and Skin CancerImmunotherapy

Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In-transit Disease

Br J Dermatol.

Weber J, Glutsch V, Geissinger E, Haug L, Lock JF, Schneider F, Kneitz H, Goebeler M, Schilling B, Gesierich A

doi: 10.1111/bjd.18739.

Melanoma and Skin Cancer

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature

Melanoma Res.

Dudda M, Mann C, Heinz J, Schmidgen I, Weid F, Kühn M, Saloga J, Grabbe S, Loquai C

doi: 10.1097/CMR.0000000000000703.Visit the original publication at ncbi.nlm.nih.gov

Related content

Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review

[Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma]

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors

[Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab]

Autoimmune-related bleeding occurring during combined immunotherapy for lung cancer - Case report

Acquired generalized lipodystrophy under immune checkpoint inhibition

Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In-transit Disease

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature